Should men with serum prostate-specific antigen ≤4 ng/ml and normal digital rectal examination undergo a prostate biopsy? A literature review

Oncology

Volumn 70, Issue 2, 2006, Pages 81-89

  Pepe, Pietro ^a   Panella, Paolo ^a   D'Arrigo, Letterio ^a   Savoca, Francesco ^a   Pennisi, Michele ^a   Aragona, Francesco ^a  

^a CANNIZZARO HOSPITAL   (Italy)

Author keywords

Biopsy; Prostate cancer; Prostate specific antigen; Radical prostatectomy; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AUTOPSY; CANCER SCREENING; CANCER STAGING; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; TUMOR BIOPSY; TUMOR VOLUME;

AGE OF ONSET; BIOPSY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; HUMANS; INCIDENCE; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 33646807482     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092583     Document Type: Review

References (94)

1. Ciatto S: Reliability of PSA testing remains unclear (letter). BMJ 2003;327:750.
2. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whitemore AS, Schmid HP: Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(suppl):933-938.
3. Ohori M, Wheeler T, Dunn J, Stamey T, Scardino P: The pathologic features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994;152:1714-1720.
4. Epstein J, Walsh P, Carmichael M: Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
5. DiGiuseppe JA, Sauvageot J, Epstein JI: Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol 1997;21:174-178.
6. Greene DR, Rogerts E, Wessels EC, Wheeler TM, Taylor SR, Santucci RA: Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 1994;151:1301-1303.
7. Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M: Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004;172:508-511.
8. Klein EA: What is 'insignificant' prostate carcinoma? Cancer 2004;101:1923-1925.
9. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE: The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-295.
10. Hirano D, Werahera PN, Crawford ED: Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and life expectancy. J Urol 1998;159:1265-1269.
11. Bostwick DG, Grignon DJ, Hammond EH, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbro JW: Prognostic factors in prostate cancer. College of American Pathologist Consensus Statement 1999. Arch Pathol Lab Med 2000;124:995-1000.
12. Humphrey PA: Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17:292-306.
13. Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG: Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol 1998;33:261-270.
14. Lattouf JB, Saad F: Gleason score on biopsy: is it reliable for predicting the final grade on pathology? BJU Int 2002;90:694-697.
15. Sved P, Gomez P, Manoharan M, Jim S, Soloway M: Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol 2004;172:98-102.
16. Epstein JI, Potter SR: The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol 2001;166:402-410.
17. Carlson GD, Calvanese CB, Kahane H, Epstein JI: Accuracy of biopsy Gleason scores from a large uropathology laboratory: use of a diagnostic protocol to minimize observer variability. Urology 1998;51:525-527.
18. Scherr D, Swindle PW, Scardino PT, National Comprehensive Cancer Network: National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003;61(2 suppl 1):14-24.
19. San Francisco IF, DeWolf WC, Rosen S, Upton M, Olumi AF: Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol 2003;169:136-140.
20. Emiliozzi P, Maymone S, Paterno A, Scarpone P, Amini M, Proietti G, Cordahi M, Pansadoro V: Increased accuracy of biopsy Gleason score obtained by extended needle biopsy. J Urol 2004;172:2224-2226.
21. Naya Y, Ochiai A, Troncoso P, Babaian RJ: A comparison of extended biopsy and sextant biopsy scheme predicting the pathological stage of prostate cancer. J Urol 2004;171:2203-2208.
22. Goto Y, Ohori M, Arakawa A, Kattan M, Wheeler T, Scardino P: Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996;156:1059-1063.
23. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB: Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total PSA levels and needle biopsy findings. J Urol 1998;160:2407-2411.
24. Augustin H, Hammerer P, Graefen M, Erbersdobler A, Blonski J, Palisaar J, Daghofer F, Huland H: Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 2003;43:455-460.
25. Smith R, Malkowicz S, Whittington R, Van Arsdalen K, Tochner Z, Wein A: Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med 2004;164:1227-1230.
26. Poulos CK, Daggy JK, Cheng L: Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens. Cancer 2004;101:527-532.
27. Pepe P, Galia A, Fraggetta F, Grasso G, Allegro R, Aragona F: Prediction by quantitative histology of pathological stage in prostate cancer. Eur J Surg Oncol 2005;31:309-313.
28. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA: Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004;64:544-550.
29. Cupp MR, Bostwick DG, Myers RP, Oesterling JE: The volume of prostate cancer ill the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995;153:1543-1548.
30. Weldon VE, Tavel FR, Neuwirth H, Cohen R: Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. J Urol 1995;154:1074-1077.
31. Gardner TA, Lemer ML, Schlegel PN: Microfocal prostate cancer: biopsy cancer volume does not predict actual tumor volume. Br J Urol 1998;81:839-843.
32. Elgamal AA, van Poppel HP, van der Voorde WM, van Dorpe JA, Oyen RH, Baert LV: Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol 1997;157:244-246.
33. Thorson P, Arcangeli C, Keetch PA, Humphrey PA: Diagnostic features and follow-up of minimal carcinoma in prostate needle biopsies. Mod Pathol 1997;10:524.
34. Carter HB, Walsh PC, Landis P, Epstein JI: Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002;167:1231-1234.
35. Foley CL, Bott SR, Thomas K, Parkinson MC, Kirby RS: A large prostate at radical retropubic prostatectomy does nor adversely affect cancer control, continence and potency rates. BJU Int 2003;92:370-374.
36. Humphrey P, Keetch D, Smith D, Shepherd D, Catalona W: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996;155:816-820.
37. Lerner SE, Seay TM, Blute ML, Bergstralh E, Barrett D, Zincke H: Prostate specific antigen detected prostate cancer (clinical stage T1c): An interim analysis. J Urol 1996;155:821-826.
38. Noguchi M, Stamey T, McNeal J, Yemoto C: Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001;166:104-109.
39. Brossner C, Bayer G, Madersbacher S, Kuber W, Klinger C, Pycha A: Twelve prostate biopsies detect significant cancer volumes (>0.5 ml). BJU Int 2000;85:705-707.
40. Chan TY, Chan DY, Stutzman KL, Epstein JI: Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J Urol 2001;166:2181-2184.
41. Catalona W, Smith D, Ornstein D: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-1455.
42. Smith D, Carvalhal G, Mager D: Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 1998;160:1734-1738.
43. Djavan B, Zlotta A, Kratzik C, Remzi M, Seitz C, Schulmann C, et al: PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/ml. Urology 1999;54:517-522.
44. Okihara K, Fritsche H, Ayala A, Johnston D, Allard W, Babaian R: Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml. J Urol 2001;165:1930-1936.
45. Babaian R, Johnston D, Naccarato W: The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001;165:757-760.
46. Krumholtz J, Carvalhal G, Ramos C, Smith D, Thorson P, Yan Y, Humphrey P, Roehl K, Catalona W: Prostate specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002;60:469-473.
47. Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H, Minasian L, Ford L, Lippman S, Crawford E, Crowley J, Coltman C: Prevalence of prostate cancer among men with a prostate specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004;350:2239-2246.
48. Horninger W, Berger A, Roagatsch A, Gschwendtner A, Steiner H, Niescher M, et al: Characteristics of prostate cancers detected at low PSA levels. Prostate 2004;58:232-237.
49. Gilbert SM, Cavallo CB, Kahane H, Lowe FC: Evidence suggesting PSA cutpoint of 2.5 ng/ml for prompting prostate biopsy: review of 36,316 biopsies. Urology 2005;65:549-553.
50. Kobayashi T, Nishizawa K, Ogura K, Mitsumori K, Ide Y: Detection of prostate cancer in men with prostate specific antigen levels of 2.0 to 4.0 ng/ml equivalent to that in men with 4.1 to 10.0 ng/ml in a Japanese population. Urology 2004;63:727-731.
51. Schroeder F, van der Cruijsen-Koeter I, de Koning H, Vis AN, Hoedemaeker RF, Kranse R: Prostate cancer detection at low prostate specific antigen. J Urol 2000;163:806-812.
52. Gómez de Vicente J, Luján Galán M, Páez Borda A, et al: Detección del cáncer de próstata en el rango de PSA entre 3 y 3,9 ng/ml. Actas Urol Esp 2002;26:271-274.
53. Hugosson J, Aus G, Lilja H, Lodding P, Pihl C: Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397-1405.
54. Sokoloff M, Yang X, Fumo M, Mhoon D, Brendler C: Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of <4 ng/ml. BJU Int 2004;93:499-502.
55. Horninger W, Volgger H, Rogatsch H: Consideration of low PSA cut off levels to optimize the detection of curable prostate cancer. Eur Urol 2001;39(suppl 4):43-46.
56. Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ: Relationship between initial PSA level and subsequent prostate cancer detection in a longitudinal screening study. J Urol 2004;172:90-93.
57. Scott R, Matchnik D, Laskowski T, Schmalforst W: Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance J Urol 1969;101:602-607.
58. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379-385.
59. Winfield H, Reddy P, Lange P: Coexisting adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for bladder cancer. Urology 1987;30:100-101.
60. Pritchett TR, Moreno J, Warner NE, Lieskovsky G, Nichols PW, Cook BA: Unsuspected prostatic adenocarcinoma in patients who have undergone radical cystoprostatectomy for transitional cell carcinoma of the bladder. J Urol 1988;139:1214-1216.
61. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA: Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol 1989;141:1091-1094.
62. Montie JE, Wood DP, Pontes JE, Boyett JM, Levin HS: Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 1989;63:381-385.
63. Abbas F, Hochberg D, Civantos F, Soloway M: Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer. Eur Urol 1996;30:322-326.
64. Moutzouris G, Barbatis C, Plastiras D, Mertziotis N, Katsifotis C, Presvalos V, Theodorou C: Incidence and histological findings of unsuspected prostatic adenocarcinoma in radical cystoprostatectomy for transitional cell carcinoma of the bladder. Scand J Urol Nephrol 1999;33:27-30.
65. Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA, Shappell SB: Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol 2004;171:646-651.
66. Ward JF, Bartsch G, Sebo TJ, Pinggera GM, Blute ML, Zincke H: Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/ml) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? Urol Oncol 2004;22:40-47.
67. Montironi R, Mazzucchelli R, Santinelli A, Scarpelli M, Beltran AL, Bostwick D: Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric comparison with clinically detected cancer in totally embedded specimens. Hum Pathol 2005;36:646-654.
68. Kotake T, Kiyohama H: Multiple primary cancers associated with bladder cancer. An analysis of the clinical and autopsy cases in Japan. Jpn J Clin Oncol 1985;15:201-210.
69. Kantor AF, McLaughlin JK: Second cancer following cancer of the urinary system in Connecticut 1935-1982. J Natl Cancer Inst 1985;68:149-150.
70. Crawford ED, Hirano D, Werahera PN: Computer modeling of prostate biopsy: tumor size and location - not clinical significance - determine cancer detection. J Urol 1998;159:1260-1264.
71. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examinationand serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-1290.
72. Scardino P: Early detection of prostate cancer. Urol Clin North Am 1989;16:635-655.
73. Mettlin C: The status of prostate cancer early detection. Cancer 1993;72:1050-1055.
74. Slawin K, Ohori M, Dillioglugil O, Scardino P: Screening for prostate cancer: an analysis of the early experience. CA Cancer J Clin 1995;45:134-147.
75. Makinen T, Tammela T, Hakama M, Stenman U, Rannikko S, Aro J: Tumor characteristics in a population-based prostate cancer screening trial with PSA. Clinical Cancer Res 2003;9:2435-2439.
76. de Koning H, Auvinen A, Berenguer-Sanchez A, Calais da Silva F, Ciatto S, Denis L, Gohagan J, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok PC, Schroder FH: European Randomized Screening for Prostate Cancer (ERSPC) Trial: International Prostate Cancer Screening Trials Evaluation Group: large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovarian Cancer Trial. Int J Cancer 2002;97:237-244.
77. Etzioni R, Penson DF, Legler JM, Di Tommaso D, Boer R, Gann PH, Feuer EJ: Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-990.
78. Hugosson J, Aus G, Becker C, Carlsson S, Eriksson H, Lilja H, Lodding P, Tibblin G: Would prostate cancer detected by screening with PSA develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int 2000;85:1078-1084.
79. Gann P, Hennekens C, Stampfer M: A prospective evaluation of plasma prostate specific antigen for detection of prostatic cancer. JAMA 1995;273:289-294.
80. Kuller LH, Thomas A, Grandits G, Neaton J, Multiple Risk Factor Intervention Trial Research Group: Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:373-377.
81. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD: Recommended prostate specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997;277:1456-1460.
82. Postma R, Schroder FH: Screening for prostate cancer. Eur J Cancer 2005;41:825-833.
83. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB: Low levels of prostate specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001;58:411-416.
84. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Prostate Cancer Early Detection, version 1.2004. www.nccn.org.
85. Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J: Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 2005;165:1857-1861.
86. Carter HB, Landis PR, Metter EJ, Fleisher LA, Pearson JD: Prostate-specific antigen testing of older men. J Natl Cancer Inst 1999;91:1733-1737.
87. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM: Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003;349:335-342.
88. Labrie F, Candas B, Cusan L, Gomez J, Belanger A, Brousseau G, Chevrette E, Levesque J: Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004;59:311-318.
89. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-1301.
90. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO: Natural history of early, localized prostate cancer. JAMA 2004;291:2713-2719.
91. Carter HB: Prostate cancers in men with low PSA levels - must we find them? N Engl J Med 2004;350:2292-2294.
92. Hoffman R, Clanon D, Littenberg B, Frank JJ, Peirce JC: Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med 2000;15:739-748.
93. Raaijmakers R, Blijenberg BG, Finlay JA, Rittenhouse HG, Wildhagen MF, Roobol JM, Schroder FH: Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J Urol 2004;171:2245-2249.
94. Aragona F, Pepe P, Motta M, Saita A, Raciti G, La Rosa P, Nicolosi D, Dammino A, Minaldi G, Rizza G, Azzarello G, Aragona C, Rotondo S, Orestano L, Serrao A, Amico F, Dibenedetto G, Cosentino V, Iurato C, Raffino S, Gulletta M, Calarco A, Paola Q, Barbera M, Gulino G, Capizzi G, Orestano F: Incidence of prostate cancer in Sicily: results of a multicenter case-findings protocol. Eur Urol 2005;47:569-574.